These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7867659)

  • 1. Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders.
    Cereda E; Brambilla A; Ezhaya A; Gaida W; Mendla K; Monferini E; Pitsikas N; Schiavi GB; Sagrada A
    Eur J Drug Metab Pharmacokinet; 1994; 19(3):179-83. PubMed ID: 7867659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
    Bromidge SM; Brown F; Cassidy F; Clark MS; Dabbs S; Hadley MS; Hawkins J; Loudon JM; Naylor CB; Orlek BS; Riley GJ
    J Med Chem; 1997 Dec; 40(26):4265-80. PubMed ID: 9435896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives.
    Dei S; Angeli P; Bellucci C; Buccioni M; Gualtieri F; Marucci G; Manetti D; Matucci R; Romanelli MN; Scapecchi S; Teodori E
    Biochem Pharmacol; 2005 Jun; 69(11):1637-45. PubMed ID: 15896343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.
    Wienrich M; Meier D; Ensinger HA; Gaida W; Raschig A; Walland A; Hammer R
    Life Sci; 2001 Apr; 68(22-23):2593-600. PubMed ID: 11392631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD; Murkitt KL; Ho M; Watson JM; Brown F; Hunter AJ; Middlemiss DN
    Br J Pharmacol; 1999 Apr; 126(7):1620-4. PubMed ID: 10323594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of the enantiomers of aceclidine with subtypes of the muscarinic receptor.
    Ehlert FJ; Griffin MT; Glidden PF
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1335-44. PubMed ID: 8968358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
    Pei XF; Gupta TH; Badio B; Padgett WL; Daly JW
    J Med Chem; 1998 Jun; 41(12):2047-55. PubMed ID: 9622546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells.
    Olianas MC; Maullu C; Onali P
    Neuropsychopharmacology; 1999 Mar; 20(3):263-70. PubMed ID: 10063486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
    Greig NH; Reale M; Tata AM
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):123-41. PubMed ID: 23597304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.
    Akam EC; Challiss RA; Nahorski SR
    Br J Pharmacol; 2001 Feb; 132(4):950-8. PubMed ID: 11181437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
    Vamvakidès A
    Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.
    Jaen J; Barrett S; Brann M; Callahan M; Davis R; Doyle P; Eubanks D; Lauffer D; Lauffer L; Lipinski W
    Life Sci; 1995; 56(11-12):845-52. PubMed ID: 10188784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
    Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
    J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase.
    Wotta DR; Wattenberg EV; Langason RB; el-Fakahany EE
    Pharmacology; 1998 Apr; 56(4):175-86. PubMed ID: 9566019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.